Dr. Kwame S. Amankwah, MD

Dr. Amankwah practices at Uconn Health Carole and Ray Neag Comprehensive Cancer Center - HOPD in Farmington, Connecticut.

Dr. Amankwah's NPI, 1508815762, was assigned on May 8, 2006. Dr. Amankwah graduated from Albany Medical College in 1997. Dr. Amankwah's Connecticut license number on file is 040506.

Dr. Amankwah's primary practice is Uconn Health Carole and Ray Neag Comprehensive Cancer Center - HOPD, at 263 Farmington Ave, Farmington, CT 06030.

Dr. Amankwah's primary practice is Uconn Health Carole and Ray Neag Comprehensive Cancer Center - HOPD in Farmington, Connecticut. Dr. Amankwah is also affiliated with UConn John Dempsey Hospital. The medical group on file is UConn Medical Group. Dmand AI also links Dr. Amankwah to 2 more hospitals, 2 medical groups and 1 home health agency, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Amankwah practices, 5 sites in all. Vendor and product names are available with a free account.

Vascular surgery is Dr. Amankwah's primary specialty in the NPI Registry, under taxonomy code 2086S0129X. Dr. Amankwah is board certified in surgery by the American Board of Surgery. Dmand AI has Dr. Amankwah's licenses on file in 2 states: Connecticut and New York.

Dmand AI lists amputation, arterial blot clot /embolism, blood vessel access for dialysis, carotid revascularization, circulatory problems in extremities, deep vein thrombosis (DVT), heart device and aorta surgery and peripheral vascular disease among the conditions Dr. Amankwah treats.

CMS data shows 304 Medicare services from Dr. Amankwah across 12 procedure codes in 2024, for 167 Medicare patients. Medicare paid $27,385 for them. Every service was in an office.

CMS counts 167 Medicare patients who saw Dr. Amankwah in 2024. The largest group is 75 to 84, with 66 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 31% are also on Medicaid. Their average risk score is 2.04, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Amankwah's median patient age at 72, with 47% women.

In 2024, Dr. Amankwah wrote 61 Medicare Part D claims for 19 patients. 90% of them were for generic drugs. CMS names the drug for 13 of them, across 1 drug with 11 or more claims each, at $129 in total drug cost. In 2023, CMS named 12 claims across 1 drug.

Dr. Amankwah accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Leg revascularization (restoring blood flow): 1 to 10 procedures (CMS shows small counts as a range)

Removal of tissue: 1 to 10 procedures (CMS shows small counts as a range)

Spinal fusion: 1 to 10 procedures (CMS shows small counts as a range)

Varicose vein removal: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 39 papers to Dr. Amankwah, published from 2009 to 2025. 2022 was the busiest year, with 5. The most frequent topics are Blood Vessel Prosthesis Implantation, Education, Medical, Graduate and Vascular Surgical Procedures. Dr. Amankwah has published most often in J Vasc Surg. Dr. Amankwah's most frequent co-authors are Michael J. Costanza, MD, Matthew Russell Smeds, MD and Vivian Gahtan, MD.

Dmand AI links Dr. Amankwah to 1 clinical trial. Conditions studied include Pulmonary Embolism and Embolism.

CMS Open Payments shows 74 general payments to Dr. Amankwah from 23 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 66% of the total. Volcano Corporation paid the most, $2,100.

Dmand AI lists 2 awards for Dr. Amankwah.

Dr. Amankwah graduated from Albany Medical College in 1997. Dr. Amankwah is a member of ACS.

Dr. Amankwah is in network with 16 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.